Related Experiment Video

Updated: Jun 24, 2026

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia
04:32

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia

Published on: June 28, 2018

Late onset ventilator-associated pneumonia due to multidrug-resistant Acinetobacter spp.: experience with tigecycline

D Curcio1, F Fernández, J Vergara

  • 1Infectología Institucional SRL, Buenos Aires, Argentina. djcurcio@gmail.com

Journal of Chemotherapy (Florence, Italy)
|March 20, 2009
PubMed

Insights

Tigecycline shows a 69.86% clinical success rate for treating ventilator-associated pneumonia (VAP) caused by multidrug-resistant Acinetobacter spp. Older age and non-bronchoalveolar lavage sampling predict negative outcomes.

Area of Science:

  • Infectious Diseases
  • Critical Care Medicine
  • Antimicrobial Stewardship

Background:

  • Ventilator-associated pneumonia (VAP) poses a significant challenge, particularly when caused by multidrug-resistant (MDR) Acinetobacter spp.
  • Limited treatment options exist for VAP due to MDR Acinetobacter infections, necessitating evaluation of alternative therapies.

Purpose of the Study:

  • To assess the clinical success rate of tigecycline in treating VAP caused by MDR Acinetobacter spp.
  • To identify predictor variables associated with clinical outcomes in this patient population.

Main Methods:

  • A retrospective study evaluating 73 patients with VAP due to MDR Acinetobacter spp. treated with tigecycline across seven intensive care units.
  • Analysis of clinical success rates and identification of significant predictor variables for treatment outcomes.

Main Results:

  • Overall clinical success rate with tigecycline was 69.86% (51/73 patients).
  • No significant differences in success rates were observed based on carbapenem resistance or prior antibiotic duration.
  • Age over 67 and non-bronchoalveolar lavage (BAL) respiratory sampling were identified as predictors of negative clinical outcomes.

Conclusions:

  • Tigecycline appears to be a viable therapeutic option for VAP caused by MDR Acinetobacter spp.
  • Further evidence from controlled clinical trials is needed to support tigecycline's approval for new indications in VAP treatment.

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: